Maxi Zumpe

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 12

Top Topics

Acute Lymphoblastic Leukemia

Immune Response

Clinical Evaluation

Top Venues

Journal of neuro-oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Holger N Lode, Ruth Ladenstein, Sascha Troschke-Meurer, Linda Struppe, Nikolai Siebert, Maxi Zumpe, Karoline Ehlert, Stefanie Huber, Evgenia Glogova, Patrick Hundsdoerfer, Angelika Eggert, Anna Zaniewska-Tekieli, Walentyna Balwierz, Aleksandra Wieczorek
Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy. Cancers 15 (13) (2023)
Sascha Troschke-Meurer, Maxi Zumpe, Lena Meißner, Nikolai Siebert, Piotr Grabarczyk, Hannes Forkel, Claudia Maletzki, Sander Bekeschus, Holger N Lode
Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models. Cancers 15 (3) (2023)
Paula Zwicker, Maxi Zumpe, Axel Kramer, Gerald Müller
A 3D Model of Human Buccal Mucosa for Compatibility Testing of Mouth Rinsing Solutions. Pharmaceutics 15 (3) (2023)
Paula Zwicker, Maxi Zumpe, Axel Kramer, Gerald Müller
A 3D Model of Human Buccal Mucosa for Compatibility Testing of Mouth Rinsing Solutions. Pharmaceutics 15 (3) (2023)
Nikolai Siebert, Maxi Zumpe, Christian Heinrich Schwencke, Simon Biskupski, Sascha Troschke-Meurer, Justus Leopold, Alexander Zikoridse, Holger N Lode
Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta. Cancers 15 (13) (2023)
Paula Zwicker, Maxi Zumpe, Axel Kramer, Gerald Müller
A 3D Model of Human Buccal Mucosa for Compatibility Testing of Mouth Rinsing Solutions. Pharmaceutics 15 (3) (2023)
Sascha Troschke-Meurer, Maxi Zumpe, Lena Meißner, Nikolai Siebert, Piotr Grabarczyk, Hannes Forkel, Claudia Maletzki, Sander Bekeschus, Holger N Lode
Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models. Cancers 15 (3) (2023)
Leah Klingel, Nikolai Siebert, Sascha Troschke-Meurer, Maxi Zumpe, Karoline Ehlert, Stefanie Huber, Hans Loibner, Oliver Mutschlechner, Holger N Lode
Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments. Cancers 14 (23) (2022)
Nikolai Siebert, Justus Leopold, Maxi Zumpe, Sascha Troschke-Meurer, Simon Biskupski, Alexander Zikoridse, Holger N Lode
The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD 2 Antibody Dinutuximab Beta. Cancers 14 (19) (2022)
Leah Klingel, Nikolai Siebert, Sascha Troschke-Meurer, Maxi Zumpe, Karoline Ehlert, Stefanie Huber, Hans Loibner, Oliver Mutschlechner, Holger N Lode
Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments. Cancers 14 (23) (2022)
Leah Klingel, Nikolai Siebert, Sascha Troschke-Meurer, Maxi Zumpe, Karoline Ehlert, Stefanie Huber, Hans Loibner, Oliver Mutschlechner, Holger N Lode
Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments. Cancers 14 (23) (2022)
Sascha Marx, Fabian Wilken, Isabel Wagner, Madlen Marx, Sascha Troschke-Meurer, Maxi Zumpe, Sandra Bien-Moeller, Martin Weidemeier, Joerg Baldauf, Steffen K Fleck, Bernhard H Rauch, Henry W S Schroeder, Holger N Lode, Nikolai Siebert
GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma. Journal of neuro-oncology 147 (3) (2020)